Clinical Trials Logo
  1. Home
  2. Atopic Dermatitis (AD)
  3. NCT04056130

A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

Atopic Dermatitis (AD) Clinical Trial

Official title:
A Phase I Randomized Double-blind Placebo-controlled Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

Clinical Trial Summary

The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).

Clinical Trial Description

This is a randomized double-blind, placebo-controlled, single centre Phase I study. Thirty-six (36) subjects are planned to be randomised at 1 site across the 2 parts of the study as follows: - Part A (Single Ascending Dose (SAD) in healthy subjects) - Part B (Multiple Ascending Doses (MAD) in healthy subjects) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04056130
Study type Interventional
Source KoBioLabs
Contact
Status Completed
Phase Phase 1
Start date October 4, 2019
Completion date January 7, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03151148 - Targeted Microbiome Transplant in Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05456529 - Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis Phase 3
Recruiting NCT04173442 - Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Completed NCT05372653 - A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis Phase 3
Completed NCT03168113 - Atopic Dermatitis (AD) and Food Allergy N/A
Terminated NCT03389893 - Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis Phase 4
Recruiting NCT04541810 - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Completed NCT02357940 - Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema N/A
Recruiting NCT05667623 - To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD Phase 3
Recruiting NCT05650320 - To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD Phase 3
Completed NCT01979016 - Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Phase 2
Withdrawn NCT04666675 - A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil Phase 3
Active, not recruiting NCT05959083 - Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
No longer available NCT04159597 - Expanded Access to Upadacitinib